Regulation of Bcl-2 during androgen-unresponsive progression of prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 5, Issue 3, 2002, Pages 236-245

  Rothermund, C A ^a   Kondrikov, D ^a   Lin, M F ^a   Vishwanatha, J K ^a  

^a NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Androgen unresponsive; Apoptosis; Bcl 2; LNCaP; Prostate cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BUTYRIC ACID; MESSENGER RNA; PACLITAXEL; PROTEIN BAX; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CELL GROWTH; CONTROLLED STUDY; HORMONE RESPONSE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MULTIGENE FAMILY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FAMILY; REGULATORY MECHANISM; WESTERN BLOTTING;

ANDROGENS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BUTYRATES; DISEASE PROGRESSION; HUMANS; MALE; MICROSCOPY, CONFOCAL; OXIDATIVE STRESS; PACLITAXEL; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED;

EID: 0036388205     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500582     Document Type: Article

References (22)

1. Boring CC, Squires TS, Tong T. Cancer statistics. CA Cancer Journal Clinicians 1993; 43: 7-26.
2. Denis L, Murphy GP. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer 1993; 72(Suppl): 3888-3895.
3. Denmeade SR, Isaacs JT. Activation of programmed (apoptotic) cell death for the treatment of prostate cancer. Advances Pharmacol 1996; 35: 281-306.
4. Tang DG, Porter AT. Target to apoptosis: a hopeful weapon for prostate cancer. The Prostate 1997; 32: 284-293.
5. Basu A, Haldar S. The relationship between Bcl-2, Bax and p53: consequences for cell cycle progression and cell death. Mol Human Repro 1998; 12: 1099-1109.
6. Cardillo M et al. Resistance to apoptosis and up regulation of Bcl-2 in benign prostatic hyperplasia after androgen deprivation. J Urol 1999; 158: 212-216.
7. Tang DG, Li L, Chopra DP, Porter AT. Extended survivability of prostate cancer cells in the absence of trophic factors: increased proliferation, evasion of apoptosis, and the role of apoptosis proteins. Cancer Res 1998; 58: 3466-3479.
8. Carroll AG, Voeller HJ, Sugars L, Gelmann EP. p53 oncogene mutations in three human prostate cancer cell lines. Prostate 1993; 23: 123-134.
9. Lin MF et al. Expression of human prostatic acid phosphatase correlates with androgen-stimulated cell proliferation in prostate cancer cell lines. J Biol Chem 1998; 273: 5939-5947.
10. Mitchell S et al. Phenotypic and genotypic characterization of commonly used human prostatic cell lines. Br J Uro 2000; 85: 932-944.
11. Veldscholte J et al. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol 1992; 41: 665-669.
12. Veldscholte J et al. Unusual specificity of the androgen receptor in the human prostate tumor cell line LNCaP: high affinity for progestagenic and estrogenic steroids. Biochim Biophys Acta 1990; 1052: 187-194.
13. Gao M, Ossowski L, Ferrari AC. Activation of Rb and decline in androgen receptor protein precede retinoic acid-induced apoptosis in androgen-dependent LNCaP cells and their androgen-independent derivative. J Cell Physiol 1999; 179: 336-346.
14. Navone NM et al. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer. Clin Cancer Res 2000; 6: 1190-1197.
15. Rokhlin OW et al. Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res 1997; 57: 1758-1768.
16. Blagosklonny MV et al. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res 1996; 56: 1851-1854.
17. Haldar S, Chintapalli J, Croce CM. Taxol induces Bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 1996; 56: 1253-1255.
18. Breitschopf K et al. Post-translational modification of Bcl-2 facilitates. Its proteasome-dependent degradation: molecular characterization of the involved signaling pathway. Mol Cell Biol 2000; 20: 1886-1896.
19. Srivastava RK, Mi QS, Hardwick JM, Longo DL. Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc Natl Acad Sci, USA 1999; 96: 3775-3780.
20. Gross A, McDonnell JM, Korsmeyer SJ. Bcl-2 family members and the mitochondria in apoptosis. Genes Devel 1999; 13: 1899-1911.
21. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998; 281: 1322-1326.
22. Lebedeva I et al. Bcl-xL in prostate cancer cells: effects of over-expression and down-regulation on chemosensitivity. Cancer Res 2000; 60: 6052-6060.